Lineweaver Wealth Advisors LLC Acquires 909 Shares of Johnson & Johnson (NYSE:JNJ)

Lineweaver Wealth Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 15,816 shares of the company’s stock after purchasing an additional 909 shares during the period. Johnson & Johnson accounts for 0.8% of Lineweaver Wealth Advisors LLC’s investment portfolio, making the stock its 27th largest holding. Lineweaver Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,579,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at $39,000. Cardinal Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 333.3% in the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the last quarter. First Bank & Trust increased its holdings in shares of Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after purchasing an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at $84,000. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Sanford C. Bernstein reduced their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Raymond James reduced their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Citigroup boosted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, Morgan Stanley reduced their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Stock Down 0.3 %

JNJ stock opened at $168.31 on Tuesday. The stock has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a 50-day moving average price of $176.07 and a 200-day moving average price of $171.13.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Insider Transactions at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Ashley Mcevoy sold 73,323 shares of the company’s stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is currently owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.